Enterobiotix raised £19 million (about $25.7 million) to fund Phase 2b development of its lead microbiome program EBX-102-02 for irritable bowel syndrome with constipation (IBS-C). The company’s financing supports clinical expansion and further evaluation of its oral microbiome-based approach. The round’s timing indicates continued investor appetite for gut-microbiome therapeutics moving from earlier studies into larger, more discriminating efficacy trials. For sponsors, IBS-C remains a competitive indication with multiple mechanisms and endpoints, making trial design and responder definitions decisive. Investors and clinicians will watch how EBX-102-02 performs on symptom-related endpoints and whether changes in microbiome composition translate into clinically meaningful improvements. The funding also highlights a broader pipeline pattern: microbiome startups increasingly rely on milestone-based capital to reach Phase 2 proof-of-concept before seeking strategic partnerships.